INDUSTRY BENCHMARKING REPORT: A STUDY OF GLOBAL AND REGIONAL TRENDS 2019

Ahead of Pharma Brand Protection and Anti-Counterfeit Summit, we conducted an industry-wide survey to understand the threats faced by pharma manufacturers with regards to supply chain security and where they are prioritising investment in order to maximise their brand and product protection. The report provides a comparison of global and...

3 Reasons to Capitalize on New Anti-Counterfeiting & Brand Protection Technologies in 2019

A new survey by Strategy&, PwC’s strategy consulting business, has found that pharmaceutical executives generally aren’t inclined to spend more to fight fakes, despite their awareness that current measures don’t go far enough. Not only do these executives misjudge their own vulnerability, but they also overlook the opportunities awaiting those...

Finding Fake Medicines

Estimates suggest that the global counterfeit drug market sits somewhere between US$75 and $200 billion and represents 10–50 percent of all drugs sold in some low-income countries. This article looks at the past, present, and future of counterfeit drug screening.

The Growing Danger of Online Pharmacies

Ahead of the Pharmaceutical Brand Protection and Anti-Counterfeiting Conference, we took a look at INTERPOL's largest counterfeit seizures in 2018.Download this piece to learn more about:Operation highlights from the U.S. Food and Drug AdministrationTrends deducted from this year's Pangea Enforcement OperationINTERPOL’S other major operations to combat the sale of illegal...

2019 Exclusive Interview: The Impact of EU FMD on Brand Protection Strategy

Is your brand protection strategy compliant with the EU regulations in 2019? As the EU FMD has recently come into full force, we wanted to understand what it would mean for serialisation managers and industry professionals, and how it will affect a pharmaceutical company's brand protection strategy.In our exclusive interview...